08 Jun 2022
Evgen Pharma - Full-year results: SFX-01 clinical focus for the year ahead
Evgen reported full-year results to end March 2022 with a pre-tax loss of £3.1m slightly better than our forecast loss of £3.3m. As a result, net cash and short-term investments were also higher at £9m vs £7.6m. The Group made good pre-clinical progress on several fronts during the year on lead asset SFX-01 including in cdk4/6 resistant breast cancer, glioblastoma (including US FDA Orphan Drug Designation), Juvenile Myelomonocytic Leukaemia, scale up of manufacturing and formulation improvements ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Evgen Pharma - Full-year results: SFX-01 clinical focus for the year ahead
Evgen Pharma Plc (EVG:LON) | 0.8 0 0.0% | Mkt Cap: 3.42m
- Published:
08 Jun 2022 -
Author:
Mark Brewer | Cavendish Research -
Pages:
9
Evgen reported full-year results to end March 2022 with a pre-tax loss of £3.1m slightly better than our forecast loss of £3.3m. As a result, net cash and short-term investments were also higher at £9m vs £7.6m. The Group made good pre-clinical progress on several fronts during the year on lead asset SFX-01 including in cdk4/6 resistant breast cancer, glioblastoma (including US FDA Orphan Drug Designation), Juvenile Myelomonocytic Leukaemia, scale up of manufacturing and formulation improvements ....